Bernard Davitian to Exit Board of Lexeo Therapeutics
Company Announcements

Bernard Davitian to Exit Board of Lexeo Therapeutics

Lexeo Therapeutics, Inc. (LXEO) has issued an update.

Bernard Davitian has informed Lexeo Therapeutics, Inc. that he will not seek re-election at the upcoming annual stockholders’ meeting. This decision is not fueled by any disputes or disagreements over the company’s operational, policy, or practice matters.

See more data about LXEO stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyLexeo Therapeutics price target lowered to $21 from $22 at H.C. Wainwright
TheFlyLexeo Therapeutics reports Q2 EPS (64c), consensus (69c)
GlobeNewswireLexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!